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Abstract
Background: Borderline resectable pancreatic cancers infiltrate into adjacent vascular structures to an extent that
makes an R0 resection unlikely when pancreatectomy is performed de novo. In a pilot study, Alliance for Clinical
Trials in Oncology Trial A021101, the median survival of patients who received chemotherapy and radiation prior to
anticipated pancreatectomy was 22 months, and 64% of operations achieved an R0 resection. However, the individual
contributions of preoperative chemotherapy and radiation therapy to therapeutic outcome remain poorly defined.
Methods: In Alliance for Clinical Oncology Trial A021501, a recently activated randomized phase II trial, patients (N = 134)
with a CT or MRI showing a biopsy-confirmed pancreatic ductal adenocarcinoma that meets centrally-reviewed anatomic
criteria for borderline resectable disease will be randomized to receive either 8 cycles of modified FOLFIRINOX (oxaliplatin
85 mg/m2, irinotecan 180 mg/m2, leucovorin 400 mg/m2 and infusional 5-fluorouracil 2400 mg/m2 over 2 days for
4 cycles) or to 7 cycles of modified FOLFIRINOX followed by stereotactic body radiation therapy (33–40 Gy in 5 fractions).
Patients without evidence of disease progression following preoperative therapy will undergo pancreatectomy and will
subsequently receive 4 cycles of postoperative modified FOLFOX6 (oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, bolus
5-fluorouracil 400 mg/m2, and infusional 5-fluorouracil 2400 mg/m2 over 2 days for 4 cycles). The primary endpoint is
the 18-month overall survival rate of patients enrolled into each of the two treatment arms. An interim analysis of the
R0 resection rate within each arm will be conducted to assess treatment futility after accrual of 30 patients.
Secondary endpoints include rates of margin-negative resection and event-free survival. The primary analysis
will compare the 18-month overall survival rate of each arm to a historical control rate of 50%. The trial is
activated nationwide and eligible to be opened for accrual at any National Clinical Trials Network cooperative
group member site.
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Discussion: This study will help define standard preoperative treatment regimens for borderline resectable
pancreatic cancer and position the superior arm for further evaluation in future phase III trials.
Trial registration: ClinicalTrials.gov: NCT02839343, registered July 14, 2016.
Keywords: Pancreatic cancer, Borderline resectable, Pancreatoduodenectomy, Radiation, Stereotactic,
Chemotherapy, Clinical trial
Background
Borderline resectable pancreatic ductal adenocarcinomas
(PDAC), like locally advanced PDACs, infiltrate adjacent
tissues to involve adjacent mesenteric vascular structures
but the extent to which they do so is relatively minimal
so complete macroscopic resection is technically feasible
[1]. Nonetheless, their pattern of infiltration is more ex-
tensive than that of potentially resectable cancers so the
potential for microscopically incomplete (R1) operations
is significant when surgery is used as primary therapy
[2, 3]. Given that complete microscopic (R0) resection
represents a requisite component of curative treatment
for patients with PDAC, preoperative treatment
regimens designed to both optimize surgical outcomes
and to select appropriate patients for pancreatectomy
are increasingly being administered to patients with bor-
derline resectable cancers in an attempt to maximize the
likelihood for long-term survival.
The therapeutic strategy utilized most frequently for
borderline resectable PDAC is currently based entirely
upon consensus [4, 5]. Typically, patients first receive 2 to
4 months of systemic chemotherapy followed by a con-
ventionally fractionated course of radiation therapy given
over 5–6 weeks with a radiosensitizing fluoropyrimidine
or gemcitabine. Patients who complete this multimodality
regimen without evidence of disease progression undergo
pancreatectomy with curative intent; those who progress
systemically prior to the intended operation are treated
with non-surgical palliative therapies. This approach lever-
ages theoretical benefits associated with systemic chemo-
therapy (e.g., systemic antitumor activity for
micrometastatic disease known to exist in almost all pa-
tients), radiation therapy (e.g., “sterilization” of surgical
margins) and time (e.g., patient selection) in an attempt to
maximize systemic control, local control, and ultimately,
overall survival. Success with this strategy has historically
been described primarily in single-institution, retrospect-
ive reports [6]. In Alliance for Clinical Oncology Trial
A021101, a recently-published, prospective pilot trial, we
showed that this paradigm of multimodality therapy can
also be implemented effectively in a multi-institutional
setting; among 22 patients with borderline resectable
PDAC who initiated treatment, 15 (68%) underwent
pancreatectomy and the overall survival rate of all accrued
patients at 18 months was 50% [7].
This paradigm of sequential administration of chemo-
therapy and chemoradiation was proposed at a time when
gemcitabine—a systemic agent with a response rate in
PDAC of less than 10%—was standard therapy [4, 5]. In
the “gemcitabine era”, the rationale for following systemic
chemotherapy with chemoradiation was the latter’s direct
cytotoxic effect on the primary tumor, possibly leading to
an improvement in local control or downstaging of the
cancer to an extent that might facilitate an R0 resection.
However, the added benefit of conventional chemoradia-
tion remains unclear in this setting. Indeed, the sequential
administration of gemcitabine-based chemotherapy and
chemoradiation led to a radiographic response in only
12% of borderline resectable primary tumors evaluated,
and downstaged only 0.8% to technically resectable in one
large, retrospective analysis of this approach [8]. Further-
more, conventional chemoradiation as advocated in the
consensus guidelines is delivered over a duration of 5–
6 weeks prior to a 6 week break before surgery. Because
chemoradiation acts principally upon the primary tumor
and regional lymph nodes, the systemic micrometastatic
disease that appears to exist in all patients with localized
PDAC may therefore be suboptimally treated—or untrea-
ted—for as many as 3 to 4 months prior to resection using
this strategy. Further, given the proximity of the adjacent
dose-limiting stomach and small bowel, the delivery of
high doses of radiation therapy to the tumor has been
prohibited using conventionally fractionated regimens.
The consensus treatment algorithm of systemic
chemotherapy followed by conventional chemoradiation
that is now frequently used for patients with borderline
resectable PDAC requires rigorous review in the context
of significant recent advances in both medical and ra-
diation oncology. The systemic regimens now in routine
use for patients with metastatic pancreatic cancer—FOL-
FIRINOX and gemcitabine plus nab-paclitaxel—are
associated with objective response rates of 32% and 23%,
respectively, in the setting of metastatic PDAC [9, 10].
Given the relatively high response rates associated with
these regimens compared to gemcitabine alone, it is con-
ceivable that current systemic therapy may allow better
treatment of systemic disease, which represents the key
source of morbidity and mortality among patients with
PDAC, without forgoing the potential local benefits of
chemoradiation. The administration of chemotherapy
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alone in the preoperative setting for patients with both
resectable and borderline resectable cancers is not
without precedent: in a single-center study of patients
with resectable PDAC, 27 (71%) of 38 patients who
received preoperative gemcitabine and oxaliplatin under-
went surgical resection and the median OS for all 38 pa-
tients was 27.2 months [11]. A recent multi-institutional
pilot study of perioperative modified FOLFIRINOX
(mFOLFIRINOX) in 21 patients with resectable pancre-
atic cancer resulted in a 94% R0 resection rate in 17/21
able to undergo resection, and a median OS of
33.4 months [12]. And, in a retrospective evaluation of
64 patients with borderline resectable disease treated
with preoperative gemcitabine/docetaxel and other sys-
temic agents, 31 (48%) were resected and the median
OS of all 64 patients was 23.6 months [13].
Furthermore, to the extent that radiation therapy
may have a role in “sterilizing” the surgical margins
of borderline resectable tumors and thereby enhan-
cing rates of R0 resection and local control, new,
attractive alternatives such as stereotactic body radi-
ation therapy (SBRT, 6.6 Gy × 5) use a dosing sched-
ule of only 5 days. SBRT, using newer radiation
machines with image guidance, fiducial markers, and
motion management techniques, has facilitated the
delivery of higher doses to the tumor and the reduc-
tion of toxicity to normal tissues. In a multicenter
prospective study, gemcitabine followed by SBRT was
shown to be safe in patients with locally advanced
PDAC, with comparable quality of life and reduced
abdominal pain [14, 15]. Although SBRT has not been
prospectively tested in patients with borderline resec-
table PDAC, retrospective data are promising and
support prospective evaluation [16]. Importantly,
SBRT is recommended only to patients who are able
to meet specific dose constraints, who can undergo
placement of fiducial markers for targeting with daily
image guidance, and for whom techniques to suffi-
ciently reduce respiratory tumor motion to <5 mm
are available. For patients who do not meet these cri-
teria, hypofractionated image guided radiation therapy
(HIGRT, 5 Gy × 5) is an alternate strategy in which a
lower yet still potentially effective dose is delivered.
A prospective trial to further the understanding of
the relative contributions of preoperative systemic and
local therapies for patients with borderline resectable
PDAC is now timely and essential to further progress.
A021501, a collaborative randomized phase II study,
will establish a treatment strategy to which novel reg-
imens can be compared in the future. This study will
compare the efficacy of two preoperative regimens,
one of which utilizes modern systemic therapy alone
and one that uses systemic therapy and hypofractio-
nated SBRT or HIGRT.
Methods
Objectives
The primary objective of this study is to evaluate and
estimate the 18-month overall survival (OS) rate of
patients with borderline resectable PDAC receiving
preoperative therapy consisting of one of the follo-
wing regimens prior to intended surgical resection
and postoperative therapy with 4 cycles of modified
FOLFOX6 (mFOLFOX6): 1) Arm 1: 8 cycles of
systemic mFOLFIRINOX, or 2) Arm 2: 7 cycles of
systemic mFOLFIRINOX followed by hypofractionated
radiation therapy. Secondary objectives include: 1) to
evaluate and estimate the R0 resection rates in
patients receiving each of the two multimodality
treatment regimens, 2) to evaluate and estimate the
event-free survival in patients receiving each of the
two multimodality treatment regimens, 3) to evaluate
and estimate the pathologic compete response (pCR)
rates in patients receiving each of the two multimod-
ality treatment regimens, and 4) to assess the adverse
events (AE) profile and safety of each treatment arm,
using the Common Terminology Criteria for Adverse
Events (CTCAE) and the Patient Reported Outcome
version of the CTCAE (PRO-CTCAE). The study
schema is illustrated in Fig. 1. The study calendar is
illustrated in Table 1.
Setting
This study, A021501, is conducted by the Alliance for
Clinical Trials in Oncology (Alliance), collaborating with
the Southwest Oncology Group (SWOG), NRG Oncology,
and the Eastern Cooperative Oncology Group-American
College of Radiology Imaging Network (ECOG-ACRIN).
Patients will be accrued from member institutions of any
of these National Clinical Trials Network cooperative
groups. The institutional review board at each participa-
ting institution must approve the study. All patients must
provide written informed consent.
Eligibility, preregistration and registration
Registration is accomplished in two phases. Eligibility
criteria are confirmed during a preregistration phase and
include age ≥ 18 years, ECOG performance status (PS)
of 0 or 1, biopsy confirmation of adenocarcinoma of the
pancreatic head, no remote lymphadenopathy or distant
metastases, and a computed tomography (CT) or mag-
netic resonance imaging (MRI) study of the abdomen
using a pancreatic protocol and CT or MRI of the chest
demonstrating a primary tumor characterized by one or
more of the following relationships (Intergroup Criteria
[6]): 1) a tumor-vessel interface (TVI) with the mesen-
teric vein (SMV) or portal vein (PV) measuring ≥180° of
the circumference of either vein’s wall or short-segment
occlusion of either vein with a normal vein above and
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below the obstruction amenable to reconstruction; 2)
any TVI with the common hepatic artery (CHA) with a
normal artery proximal and distal to the TVI amenable
to reconstruction; and 3) a TVI with the superior mesen-
teric artery (SMA) measuring <180° of the circumference
of the vessel wall. Tumors with an interface with the
SMV and PV measuring <180° and without an interface
with either the CHA or SMA—considered borderline re-
sectable by other guidelines—are considered resectable
[5]. A TVI with the SMV, PV, or CHA but without a
normal vessel proximal and distal to the interface to
allow reconstruction, a TVI with the SMA measuring
≥180° of that vessel’s circumference, and a TVI with the
aorta are considered to represent locally advanced
disease. Patients with resectable, locally advanced or
metastatic PDAC are ineligible.
Final registration requires real-time confirmation of di-
sease stage with central review of all radiologic images and
multidisciplinary evaluation of the patient by a medical
oncologist, radiation oncologist, and surgeon. Additional
criteria included granulocytes ≥2000/μL, hemoglobin
>9 g/dL, platelets ≥100,000/μL, albumin >3.0 g/dL, cre-
atinine ≤1.5 times the upper limit of normal, aspartate
transaminase and alanine transaminase ≤2.5 times the
upper limit of normal, and bilirubin ≤2 mg/dL. Exclusion
criteria include peripheral neuropathy grade ≥ 2, prior
therapy for PDAC, Gilbert’s syndrome or homozygosity
for UGT1A1*2, and any active second malignancy.
Treatment plan
Preoperative treatment
Upon registration, patients are randomized to one of
two treatment arms. Patients in both arm 1 and arm 2
receive 4 cycles of mFOLFIRINOX (bolus intravenous
[IV] oxaliplatin 85 mg/m2, irinotecan 180 mg/m2,
leucovorin 400 mg/m2, then a 46–48-h IV infusion of 5-
fluorouracil 2400 mg/m2) with subsequent prophylactic
white blood cell growth factor support. Following the
first four cycles of mFOLFIRINOX, patients are restaged
with CT or MRI, and those without evidence of metasta-
ses and who maintain a PS of 0 or 1 receive either an
additional 4 cycles of mFOLFIRINOX (arm 1) or an
additional 3 cycles of mFOLFIRINOX followed by radio-
therapy using either SBRT (6.6 Gy × 5) or HIGRT
(5 Gy × 5).
SBRT is strongly preferred over HIGRT and it is
expected that the majority of patients eligible for this
trial will receive SBRT. Only those patients who do not
meet specific criteria as outlined in the protocol should
be offered HIGRT to ensure patient safety. SBRT allows
for simultaneous integrated boosts (SIB) to the tumor
vessel interface (TVI). In contrast, HIGRT delivers a
homogeneous dose without a boost to the TVI in order
to minimize normal tissue dose. Each site must be cre-
dentialed for SBRT prior to enrollment and all radiation
plans must be centrally reviewed prior to treatment.
Pancreas tumors are not easily seen on cone beam CT
scans at the time of SBRT. Placement of fiducial markers
under echoendoscopic guidance within or near the
tumor is required prior to radiation. An online tutorial
for SBRT planning and delivery has been created to
assist those sites who have not previously performed
pancreas SBRT (www.educase.com).
Surgical resection
Following completion of either chemotherapy alone
(arm 1) or chemotherapy followed by radiation (arm 2),
all patients are restaged with CT or MRI, and those
without locally advanced or metastatic disease on imme-
diate central radiologic review and who have a PS of 0
Fig. 1 Study calendar
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Table 1 Study calendar. Pre-Study Testing Intervals. To be completed ≤21 DAYS before registration: All laboratory studies, history
and physical. To be completed ≤28 DAYS before registration: CT/MRI scans used for staging
Prior to
Pre-Reg
Prior to
Reg*
Day 1 of each cycle
of mFOLFIR-INOX*
RT (day 1 to day 5)
(Arm 2 only)
Surgery Day 1 of each
cycle of FOLFOX *
Post Tx
Follow- up**
Tests & Observations
History and physical, weight, PS *** X [1] X [1] X [1] X [1] X [1]
Pulse, BP X [1] X [1] X [1] X [1] X [1]
Height X [1]
Adverse Event Assessment (CTCAE) † X [1] X [1] X [1] D [1] X [1]
Adverse Event Assessment (PRO-CTCAE) †† X [2] X X D X
Registration QOL/Mental Well-being/Physical
Well-being/Fatigue
X [2]
Laboratory Studies
CBC, Differential, Platelets X X X X X X
Chemistry (Serum Creatinine, Electrolytes,
AST, ALT, Alk. Phos., Albumin, Total Bilirubin)
X X X X X X
Pregnancy Test (#) X
CA 19–9 A A A A A X
RT Planning
EUS with Fiducial Placement for RT B
Staging
Staging CT Scan of Chest or Chest X-ray/CT
or MRI of Abdomen
X [3] C [3] C [3] C [3] C [3] X [3]
Central Radiographic Review C C
Central Pathology Review X [4]
Optional Correlative studies: For patients who consent to participate
Blood specimen sample (A021501-PP1) Between Registration and C1D1. See Additional file 1: Section 6.2.
Imaging (A021501-IM1) See Additional file 1: Section 6.4.2 for CT images submission time points and requirements.
*Labs completed prior to registration may be used for day 1 of cycle 1 if obtained ≤7 days prior to treatment (except pregnancy test and CA 19–9, as detailed
below). For subsequent cycles, labs, tests and observations may be obtained +/− 3 days from scheduled day of assessment. Radiographic windows are +/− 7 days
from scheduled day of assessment
**After off-treatment (evaluation of the last treatment cycle), patients will have physical examinations, labs, and staging scans every 16 weeks (+/− 28 days) until
they have reached 24 months post-registration or until documented progression, whichever occurs first. Thereafter, survival information is required every 6 months
for 5 years post-registration. For patients who discontinue treatment for progressive disease or are removed from protocol treatment, survival information is
required every 6 months for 5 years post-registration. See Additional file 1: Section 12.0 for removal of patients from protocol therapy
***Drug dosages need not be changed unless the calculated dose changes by ≥10%
1 May be performed by physician, NP, or PA responsible for oncologic care of the patient
2 To be completed after registration and ≤21 days prior to treatment. See Additional file 1: Appendix I
3 Chest scans must be CT or chest X-ray. Abdominal baseline and restaging scans can include either a CT or MRI, although CT is preferred. The same method of
scanning used at baseline must be used for all subsequent evaluations. The CT must be acquired with 3 mm or less slice thickness. See Additional file 1: Section
7.4.1 for further details. Supporting documentation is to be submitted, per Additional file 1: Section 6.1.1. The baseline scan and restaging scan after completion
of preoperative therapy/prior to surgery are to be centrally reviewed by the Alliance ICL at IROC Ohio, per Additional file 1: Section 7.4.2
4 Central Pathology review is retrospective. Sites must submit slides within 60 days of surgery of patient. See Additional file 1: Section 6.2
†Solicited AEs are to be collected starting at baseline. Routine AEs are to be collected starting after registration. See Additional file 1: Section 9.1 for the list of
solicited AEs. See Additional file 1: Section 9.4 for expedited reporting of SAEs. See Additional file 1: Section 9.2 for reporting of surgical AEs, to be completed
within 90 days after surgery
††Patients complete PRO-CTCAE by paper booklet ordered through the CTSU website. See Additional file 1: Section 9.1 for administration instructions. See Additional file
1: Appendix I for PRO-CTCAE assessments for IRB submission and review only. See Additional file 1: Section 4.5 for ordering instructions. PRO-CTCAE booklets should be
administered at the following time points: ≤ 21 days prior to treatment; day 1 of each cycle of mFOLFIRINOX (+/− 3 days); RT days 1–5 (Arm 2 only); prior to surgery
(+/− 7 days); and day 1 of each cycle of FOLFOX (+/− 3 days)
# For women of childbearing potential (see Additional file 1: Section 3.3.6). Must be done ≤7 days prior to registration
A CA19–9 may be performed <28 days prior to registration. Subsequently, CA 19–9 may be performed +/− 14 days from the scheduled date. During treatment,
CA 19–9 should be performed every 28 days. For patients who have normal CA 19–9 levels at baseline, continued testing of CA 19–9 is not required
B EUS/fiducial marker placement is mandatory for patients in the RT arm. Immediately following review of first restaging studies, planning for EUS/fiducial
placement and RT simulation should be scheduled to be performed during either cycle 5 or 6 of mFOLFIRINOX
C Restaging scans should be performed for both Arm 1 and Arm 2 at the following time points: 1. After the first 4 cycles of mFOLFIRINOX; 2. Prior to Surgery; 3.
Post-surgery but prior to first cycle of FOLFOX; 4. After 4 cycles while on FOLFOX. The baseline and restaging scan after completion of preoperative therapy and
prior to surgery are to be centrally reviewed by the Alliance ICL at IROC Ohio per Additional file 1: Section 7.4.2. After protocol treatment, scans should be
performed per the schedule indicated by footnote “**”
D Surgery-related AEs should be assessed and captured within 90 days of surgery
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or 1 are required to undergo pancreatectomy within 4–
10 weeks. Radiographic “downstaging” is not required.
The following surgical procedures are mandated: 1)
periadventitial dissection of the right lateral aspect of
the SMA [17]; 2) venous and/or short-segment hepatic
arterial resection when necessary to achieve negative
margins; and 3) evaluation of the histopathologic status
of the pancreatic and bile duct margins intraoperatively,
with re-resection when appropriate.
Postoperative treatment
Patients with a PS of 0 or 1, without prohibitive toxicity
from previous chemotherapy, and without evidence of
residual or recurrent disease on CT/MRI images are
considered for 4 cycles of postoperative mFOLFOX6
(oxaliplatin 85 mg/m2 and leucovorin 400 mg/m2 IV,
bolus 5-fluorouracil 400 mg/m2 IV, followed by a 46–48-
h IV infusion of 5-fluorouracil 2400 mg/m2).
Assessment and follow up
Radiologic response and progression are evaluated using
the Response Evaluation Criteria in Solid Tumors
(RECIST) version 1.1 guidelines [18]. Analysis of the sur-
gical specimen is performed following recommendations
of the American Joint Committee on Cancer and the
College of American Pathologists guidelines [19, 20].
Histopathologic response is centrally reviewed and charac-
terized by the extent of residual viable cancer cells in the
surgical specimen (<5% or ≥5% cancer cells) [21].
Histopathologic complete response (CR) is defined as the
absence of cancer cells in the specimen; in such cases, the
pretreatment biopsy is centrally re-reviewed. Resection
status is characterized as R0, R1 (microscopic tumor at
any margin), or R2 (macroscopically incomplete
resection).
Adverse events (AEs) are graded using the Common
Toxicity Criteria Adverse Event (CTCAE) Version 4.0
[22]. AEs are recorded during preoperative chemo-
therapy and chemoradiation, during surgery and
within the 90-day postoperative period, and during
postoperative therapy.
Patients are followed every 4 months following
treatment until 24 months post registration or until
documented progression of disease. All visits include
a history and physical examination, laboratory studies,
and CT or MRI of the chest and abdomen. The
appearance of any new lesion with characteristics of
local relapse or metastatic disease is considered recur-
rence. Following 24 months, survival information is
required every 6 months for 5 years post-registration.
Correlative studies
Patients may also be consented to two correlative stu-
dies. The first will utilize patients’ germline DNA from a
single 10 mL blood sample acquired at registration. This
study will test the association between the rs2853564 VDR
variant and OS, and will discover novel candidate genes
associated with both OS and chemotherapeutic toxicity of
using genome-wide genotyping approaches [23]. In the
second study, standard cross-sectional imaging studies will
be used to estimate prognosis based on discrete radio-
graphic features of the primary tumor [24].
Statistics
Sample size
We anticipate enrolling a maximum of 124 evaluable
patients (62 per arm) per statistical design. An additional
10 (5 per arm) patients will be accrued to account for
cancelations, ineligibilities, major violations, and lost-to-
follow up, etc. Thus the total targeted accrual will be
134 patients. With an anticipated accrual of 4 patients
per month, the accrual period of the study is estimated
at 34 months.
Power analysis
Eligible patients will be stratified by performance status
and randomized into two treatment arms. Within each
arm, a single-arm sequential design with one interim
analysis for futility will be implemented. The final effi-
cacy analysis and interim analysis will be based on the
18-month OS rate and R0 resection rate, respectively,
and evaluated in each arm separately. The comparison
of OS between arms will be carried out only if both arms
are deemed promising at the end of the trial. A “pick-
the-winner” strategy will be implemented to choose one
treatment strategy for recommendation.
The median OS of patients treated with multimodality
therapy for borderline resectable PDAC reported in
historical studies varies from 14 to 28 months, with a
median of 21 to 22 months and an interquartile range of
about 18 to 23 months. Most of the previous studies are
retrospective single-institution studies subject to patient
selection bias, which likely skew the reported OS higher.
Thus, we consider the median OS of at most 18 months
(equivalent to 18 m OS rate of 0.50, assuming exponen-
tial survival function) which is the lower bound of the
IQR of literature reported data as the null hypothesis.
To demonstrate clinical meaningful improvement in OS,
we target an alternative hypothesis of a median OS of at
least 27 months (equivalent to 18 m OS rate of 0.63; a
50% increase in median OS time).
A maximum of 62 evaluable patients in each arm will
provide 82% power to detect an absolute improvement
of 13% in 18 months OS rate, i.e., testing alternative hy-
pothesis that the 18 months OS rate is at least 63%
against the null hypothesis that the 18 months OS rate
is at most 50%, at a one-sided significance level of 0.07.
Katz et al. BMC Cancer  (2017) 17:505 Page 6 of 8
One interim analysis will be conducted to assess treat-
ment futility for each arm separately. For each treatment
arm, the R0 resection rate will be evaluated when
surgical data become available for the first 30 evaluable
patients. If the R0 resection rate is at least 60% (null
hypothesis), based on weighted R0 resection rate from
historical data, the arm warrants continuing to full ac-
crual for OS final analysis. If the observed R0 resection
rate is significantly less than 60%, futility of that arm has
been met and accrual of new patients to that arm will
cease. Therefore, the interim analysis based on the R0
resection rate will be testing the alternative hypothesis
of R0 resection rate ≤ 40% against the null hypothesis of
R0 resection rate ≥ 60%. The probability of stopping ac-
crual at interim is 43% and 0.8% if the true R0 resection
rate is 40% and 60%, respectively.
Discussion
Herein we describe a multi-center randomized phase II
clinical trial to be conducted in the US National Clinical
Trials Network designed to evaluate the efficacy of two
rational preoperative treatment strategies for patients
with borderline resectable PDAC. This study, A021501,
builds upon our previous work, A021101, and it will de-
fine standard preoperative treatment regimens to which
future novel regimens can and will be compared in
subsequent randomized trials.
The statistical design of this trial focuses on evaluating
whether clinical meaningful improvement in survival
can be achieved by the tested regimens compared to
historical data. This study uses a critically important
interim surrogate endpoint (R0 resection rate) that is
different from the final endpoint (18 month OS rate)
and an interim analysis which allows elimination of a fu-
tile arm after only 30 patients are enrolled to that arm.
If both arms are deemed promising at the end of the
trial, a pick-the-winner strategy will be employed to
choose one arm as the “winner”. Use of a proximate end
point, the R0 resection rate, for the interim analysis pro-
tects patients from the possibility of being randomized
to a futile arm while the whole study is still powered to
detect a clinically important and meaningful improve-
ment in the OS rate.
The concept and design of this trial was developed
and evolved by a multi-disciplinary team within the
Alliance for Clinical Trials in Oncology with the support
and critical feedback of the National Cancer Institute’s
Pancreatic Cancer Task Force and members of the other
participating cooperative groups. The trial represents a
natural next step in an investigational program that has
proceeded with the advice, investment, and involvement
of the Cancer Therapy Evaluation Program (CTEP). In-
deed, at the request of CTEP, we performed an initial
pilot study A021101 designed to rapidly assess the
feasibility of a multi-institutional study of borderline re-
sectable PDAC and to develop a standardized clinical
and research infrastructure (e.g., rapid review of im-
aging, pathologic assessments, quality control of radi-
ation protocols) specific to this disease stage that is
necessary to study it. A021101 represented one of the
most collaborative studies that has ever been conducted
in the pancreas cancer space: it met its accrual endpoint
early and within a year due to the enthusiasm of centers
within the Alliance, ECOG-ACRIN, SWOG and NRG
Oncology [7]. The trial demonstrated that rapid, real-
time central review of imaging is feasible, established
other infrastructural elements viewed as critical to the
conduct of multimodality treatment trials for pancreatic
cancer, and has set the stage for this subsequent
randomized phase II A021501 study which represents
the natural next step in this line of investigation.
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